Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.
The new accelerated approval covers the use of Scemblix for newly diagnosed patients with Philadelphia chromosome-positive ...
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback